Tasigna Tu (Nilotinib Capsule) 200mg

Tasigna TU (Nilotinib) 200mg capsules are prescribed for certain blood cancers. This oral treatment helps manage chronic myeloid leukemia by targeting cancer cells. Store at room temperature and follow healthcare provider guidance. Always consult a medical professional before use.

Strength

200mg

Pack Size

112s

Storage

Ambient

Manufacturer / TM Owner

Novartis Pharma Stein AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Nilotinib 200mg capsules are primarily used to treat chronic myeloid leukemia (CML) in adults and children. It works by slowing or stopping the growth of cancer cells in the blood. This medication is often prescribed when other treatments have not been effective. Patients may use it for long-term management under medical supervision.

Side Effects

Nilotinib capsules may help reduce symptoms associated with blood cancer, such as fatigue or swelling. Some users report improved energy levels and stabilized blood counts over time. Individual responses vary, and effects depend on consistent use as directed. Regular monitoring by a healthcare provider is recommended.

Precautions & Warnings

Keep nilotinib capsules in a cool, dry place away from moisture and direct sunlight. Always store at room temperature as indicated. Do not use if the packaging is damaged or the expiration date has passed. Keep out of reach of children and pets. Follow local disposal guidelines for unused medication.

Avoid Interactions

Nilotinib may interact with other medications, including certain antibiotics, antifungals, and heart medications. Avoid grapefruit products while taking this drug, as they can increase side effects. Alcohol and herbal supplements may also affect how nilotinib works. Always inform your healthcare provider about all medications you are taking.

References

Frequently Asked Questions

Nilotinib is used to treat chronic myeloid leukemia (CML) in adults and children.

Store nilotinib capsules at room temperature in a dry place, away from moisture and direct sunlight.

Nilotinib is typically taken on an empty stomach, but follow your healthcare provider's specific instructions.

Common side effects may include nausea, fatigue, or skin rash. Report any persistent issues to your doctor.

Nilotinib may harm an unborn baby. Consult your doctor if you are pregnant or planning pregnancy.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.